Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Indian Journal of Hematology and Blood Transfusion
Published in: Indian Journal of Hematology and Blood Transfusion 1/2023

01-06-2022 | Acute Myeloid Leukemia | Original Article

Twist1 Promoter Methylation Regulates the Proliferation and Apoptosis of Acute Myeloid Leukemia Cells via PI3K/AKT Pathway

Authors: Aihong Gong, Xiaojia Wang, Xuewei Wang, Ying Zhao, Yanan Cui

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 1/2023

Login to get access

Abstract

Twist-related protein 1 (Twist1) is a widely recognized oncogene in acute myeloid leukemia (AML), and its promoter methylation is related with the progression of solid tumors. However, the association between Twist1 promoter methylation and AML has not been well studied. Twist1 mRNA expression was detected using quantitative real-time polymerase chain reaction (qRT-PCR). The protein levels of Twist1 and phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) signal were measured via western blotting. Methylation-specific PCR was performed to detect the methylation status of Twist1 promoter. CCK-8 assay and flow cytometry were used to reveal cellular biological effects. Twist1 expression and promoter methylation level were significantly upregulated in AML tissues and cell lines and were further downregulated in demethylating agent 5′-azacitidine (5-Aza)-treated cells. Ectopic expression of Twist1 increased AML cell viability, while reducing apoptosis, and attenuated the effects of 5-Aza on the proliferation and apoptosis. We also found that the PI3K/AKT signaling pathway was positively regulated by Twist1. Our findings revealed that Twist1 accelerates the tumorigenesis of AML cells by promoting its promoter methylation via the activation of PI3K/AKT signaling pathway.
Literature
1.
De Kouchkovsky I, Abdul-Hay M (2016) Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J 6(7):e441CrossRef
2.
Pelcovits A, Niroula R (2020) Acute myeloid leukemia: a review. R I Med J (2013) 103(3):38–40
3.
Kassim AA, Savani BN (2017) Hematopoietic stem cell transplantation for acute myeloid leukemia: a review. Hematol Oncol Stem Cell Ther 10(4):245–251CrossRef
4.
Takami A (2018) Hematopoietic stem cell transplantation for acute myeloid leukemia. Int J Hematol 107(5):513–518CrossRef
5.
Medeiros BC (2018) Is there a standard of care for relapsed AML? Best Pract Res Clin Haematol 31(4):384–386CrossRef
6.
Zhang G et al (2019) High ETS2 expression predicts poor prognosis in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation. Ann Hematol 98(2):519–525CrossRef
7.
Zhao Z et al (2017) Multiple biological functions of Twist1 in various cancers. Oncotarget 8(12):20380–20393CrossRef
8.
Liu X et al (2018) Niche TWIST1 is critical for maintaining normal hematopoiesis and impeding leukemia progression. Haematologica 103(12):1969–1979CrossRef
9.
Dong CY et al (2014) Twist-1, a novel regulator of hematopoietic stem cell self-renewal and myeloid lineage development. Stem Cells 32(12):3173–3182CrossRef
10.
Chen CC et al (2015) Favorable clinical outcome and unique characteristics in association with Twist1 overexpression in de novo acute myeloid leukemia. Blood Cancer J 5:e339CrossRef
11.
Xu J et al (2016) DNMT3A mutation leads to leukemic extramedullary infiltration mediated by TWIST1. J Hematol Oncol 9(1):106CrossRef
12.
Li H et al (2020) Elevated TWIST1 expression in myelodysplastic syndromes/acute myeloid leukemia reduces efficacy of hypomethylating therapy with decitabine. Haematologica 105(10):e502CrossRef
13.
Zhu QQ et al (2016) The role of TWIST1 in epithelial-mesenchymal transition and cancers. Tumour Biol 37(1):185–197CrossRef
14.
Alaaeldin R et al (2021) Modulation of apoptosis and epithelial-mesenchymal transition E-cadherin/TGF-beta/Snail/TWIST pathways by a new ciprofloxacin chalcone in breast cancer cells. Anticancer Res 41(5):2383–2395CrossRef
15.
Gort EH et al (2008) Methylation of the TWIST1 promoter, TWIST1 mRNA levels, and immunohistochemical expression of TWIST1 in breast cancer. Cancer Epidemiol Biomark Prev 17(12):3325–3330CrossRef
16.
Ruppenthal RD et al (2011) TWIST1 promoter methylation in primary colorectal carcinoma. Pathol Oncol Res 17(4):867–872CrossRef
17.
Kwon MJ et al (2013) TWIST1 promoter methylation is associated with prognosis in tonsillar squamous cell carcinoma. Hum Pathol 44(9):1722–1729CrossRef
18.
Galvan JA et al (2015) TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelial-mesenchymal transition-like tumor budding phenotype in colorectal cancer. Oncotarget 6(2):874–885CrossRef
19.
Wang XX et al (2020) TWIST1 transcriptionally regulates glycolytic genes to promote the Warburg metabolism in pancreatic cancer. Exp Cell Res 386(1):111713CrossRef
20.
Xu Y et al (2017) Twist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expression. Oncogene 36(8):1157–1166CrossRef
21.
Liu YQ et al (2020) MiR-526b suppresses cell proliferation, cell invasion and epithelial-mesenchymal transition in breast cancer by targeting Twist1. Eur Rev Med Pharmacol Sci 24(6):3113–3121
22.
Zhao C et al (2020) Increased NFATC4 correlates With poor prognosis of AML through recruiting regulatory T cells. Front Genet 11:573124CrossRef
23.
Lao TD, Nguyen TN, Le TAH (2021) Promoter hypermethylation of tumor suppressor genes located on short arm of the chromosome 3 as potential biomarker for the diagnosis of nasopharyngeal carcinoma. Diagnostics (Basel) 11(8):1404CrossRef
24.
Fain JS et al (2021) Transcriptional overlap links DNA hypomethylation with DNA hypermethylation at adjacent promoters in cancer. Sci Rep 11(1):17346CrossRef
25.
Lee E et al (2021) recent clinical update of acute myeloid leukemia: focus on epigenetic therapies. J Korean Med Sci 36(13):e85CrossRef
26.
Samimi H et al (2021) DNA methylation analysis improves the prognostication of acute myeloid leukemia. EJHaem 2(2):211–218CrossRef
27.
Fan Z et al (2020) Targeting methyltransferase PRMT5 retards the carcinogenesis and metastasis of HNSCC via epigenetically inhibiting Twist1 transcription. Neoplasia 22(11):617–629CrossRef
28.
Wu X et al (2021) The miR-302s/367 cluster inhibits the proliferation and apoptosis in sheep fetal fibroblasts via the cell cycle and PI3K-Akt pathways. Mamm Genome 32(3):183–194CrossRef
29.
Chen Q, Wang M, Shen C (2020) Bauerane induces S-phase cell cycle arrest, apoptosis, and inhibition of proliferation of A549 human lung cancer cells through the phosphoinositide 3-kinase (PI3K)/AKT and signal transducer and activator of transcription 3 (STAT3) signaling pathway. Med Sci Monit 26:e919558
30.
Gao H et al (2021) Yiqi-Huoxue granule promotes angiogenesis of ischemic myocardium through miR-126/PI3K/Akt axis in endothelial cells. Phytomedicine 92:153713CrossRef
31.
Huang J et al (2021) MicroRNA93 knockdown inhibits acute myeloid leukemia cell growth via inactivating the PI3K/AKT pathway by upregulating DAB2. Int J Oncol 59(4):1–14CrossRef
32.
Shi M et al (2021) LncRNA-SNHG16 promotes proliferation and migration of acute myeloid leukemia cells via PTEN/PI3K/AKT axis through suppressing CELF2 protein. J Biosci 46:1–13CrossRef
33.
Zhou C et al (2021) GLI1 reduces drug sensitivity by regulating cell cycle through PI3K/AKT/GSK3/CDK pathway in acute myeloid leukemia. Cell Death Dis 12(3):231CrossRef
34.
Yuan R, Chang J, He J (2020) Effects of Twist1 on drug resistance of chronic myeloid leukemia cells through the PI3K/AKT signaling pathway. Cell Mol Biol (Noisy-le-grand) 66(6):81–85CrossRef
Metadata
Title
Twist1 Promoter Methylation Regulates the Proliferation and Apoptosis of Acute Myeloid Leukemia Cells via PI3K/AKT Pathway
Authors
Aihong Gong
Xiaojia Wang
Xuewei Wang
Ying Zhao
Yanan Cui
Publication date
01-06-2022
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 1/2023
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-022-01540-2

Other articles of this Issue 1/2023

Indian Journal of Hematology and Blood Transfusion 1/2023 Go to the issue

Short Communication

Clinical Features and Outcomes of Patients with Double-Hit/Triple-Hit Multiple Myeloma Detected at Relapse

Correspondence

Successful Treatment Of Acquired Hemophilia A Using FEIBA Supplemented With Emicizumab

Original Article

The impact of blood Transfusion on T Helper Cells and Cytokines in Transfusion-Refractory Patients: a Prospective Study

Original Article

Decrease in Mortality from Sepsis: Impact of the Multidisciplinary Program for the Hematologic Patient at Very High Risk

Original Article

Role of T Lymphocyte Activation Profile in Predicting SARS-CoV-2 Severity: Experience from Tertiary Care Centre of North India

Original Article

Demographics, Pattern of Care & Outcomes of Primary CNS Lymphoma- Experience from a Tertiary Care Cancer Center in India
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits